Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Privigen for Chronic ABMR in Kidney Transplant
NCT02374736Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2016
- Primary completion
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of intravenous immunoglobulin G in antibody mediated rejection (AMR), sponsored by Assistance publique - Hôpitaux de Paris. Started Feb 2016; status: completed.
02
Drugs
intravenous immunoglobulin G
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT02374736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02374736.